BridgeBio Pharma, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Neil Kumar
- Full Time Employees
- 839
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3160 Porter Drive Palo Alto CA United States of America 94301
- IPO Date
- Jun 27, 2019
- CIK
- 0001743881
- Website
- bridgebio.com
- Similar Companies
- Business
- BridgeBio Pharma, Inc. is a biopharmaceutical company focused on developing and delivering transformative medicines to patients with genetic diseases and cancers. The company’s core products and services include the research, development, and commercialization of novel drug candidates targeting genetic disorders and oncology indications. BridgeBio’s portfolio encompasses multiple clinical and preclinical programs across areas such as rare diseases, oncology, and precision medicine, featuring therapies in pipeline development as well as marketed products. BridgeBio operates primarily in the United States but also engages in global clinical trials and partnerships to expand its reach. Founded in 2015 and headquartered in Palo Alto, California, the company leverages its drug development expertise through subsidiaries and strategic alliances with academic institutions, pharmaceutical companies, and biotechnology firms. Recent major company developments include significant funding rounds to advance its pipeline programs; strategic partnerships to enhance its research capabilities; acquisitions aimed at broadening its therapeutic areas and bolstering its technology platforms; and the launch of new investigational drugs targeting underserved genetic conditions. These moves have reinforced BridgeBio’s commitment to advancing precision medicine and expanding its impact in the rare disease and oncology markets. The company continues to evolve its pipeline with a focus on rapid clinical development and commercialization of targeted therapies to improve patient outcomes.
BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1
Allspring Global Investments Holdings LLC Sells 104,864 Shares of BridgeBio Pharma, Inc. $BBIO
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
BridgeBio: "Strong Buy" Attruby Differentiation And Several NDA Submissions In Play
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
How a Rival's Clinical Setback Sent BBIO Stock to a 52-Week High
BridgeBio Pharma (BBIO) Moves 15.1% Higher: Will This Strength Last?
BridgeBio Stock Taps Rare Disease Trends and New Diagnosis Growth
BridgeBio Stock Outlook Hinges on Attruby & New Drug Catalysts
Is BBIO Stock a Buy Now or Too Expensive for the Risk Ahead
Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM
BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches
BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Boyd Gaming, Chipotle Mexican Grill, Conagra, Dollar General, MGM Resorts International, Omnicom Group, Yum! Brands, and More
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
Citi Initiates BridgeBio at Neutral: Why the Cardiomyopathy Story Isn't a Slam Dunk
BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches
BridgeBio Pharma, Inc. (BBIO) Presents at Bank of America Global Healthcare Conference 2026 Transcript